IL-6: a cytokine at the crossroads of autoimmunity

Current Opinion in Immunology

Volumn 55, Issue , 2018, Pages 9-14

  Jones, Britta E ^a   Maerz, Megan D ^a   Buckner, Jane H ^a  

^a BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR ANTIBODY; JANUS KINASE INHIBITOR; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL INTERACTION; CELL LINEAGE; CELL MATURATION; DISEASE ASSOCIATION; GENE EXPRESSION REGULATION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; LYMPHOCYTE FUNCTION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TFH CELL; TH17 CELL; ANIMAL; IMMUNOLOGY; INFLAMMATION;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; INFLAMMATION; INTERLEUKIN-6;

EID: 85053520353     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2018.09.002     Document Type: Review

References (60)

1. Tanaka, T., Narazaki, M., Kishimoto, T., IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol, 6, 2014, a016295.
2. Hirano, T., Matsuda, T., Turner, M., Miyasaka, N., Buchan, G., Tang, B., Sato, K., Shimizu, M., Maini, R., Feldmann, M., et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 18 (1988), 1797–1801.
3. Linker-Israeli, M., Deans, R.J., Wallace, D.J., Prehn, J., Ozeri-Chen, T., Klinenberg, J.R., Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 147 (1991), 117–123.
4. Maimone, D., Guazzi, G.C., Annunziata, P., IL-6 detection in multiple sclerosis brain. J Neurol Sci 146 (1997), 59–65.
5. Hunter, C.A., Jones, S.A., IL-6 as a keystone cytokine in health and disease. Nat Immunol 16 (2015), 448–457.
6. Kimura, A., Kishimoto, T., IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40 (2010), 1830–1835.
7. Shao, S., He, F., Yang, Y., Yuan, G., Zhang, M., Yu, X., Th17 cells in type 1 diabetes. Cell Immunol 280 (2012), 16–21.
8. Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T.B., Oukka, M., Weiner, H.L., Kuchroo, V.K., Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 (2006), 235–238.
9. Choi, S.-C., Xu, Z., Li, W., Yang, H., Roopenian, D.C., Morse, H.C., Morel, L., Relative contributions of B cells and dendritic cells from Lupus-prone mice to CD4+ T cell polarization. J Immunol, 2018, ji1701179.
10. Zhao, M., Tan, Y., Peng, Q., Huang, C., Guo, Y., Liang, G., Zhu, B., Huang, Y., Liu, A., Wang, Z., et al. IL-6/STAT3 pathway induced deficiency of RFX1 contributes to Th17-dependent autoimmune diseases via epigenetic regulation. Nat Commun, 9, 2018, 583 Novel mechanism by which IL-6 drives Th17 function via the transcription factor RFX1.
11. Ichiyama, K., Gonzalez-Martin, A., Kim, B.-S., Jin, H.Y., Jin, W., Xu, W., Sabouri-Ghomi, M., Xu, S., Zheng, P., Xiao, C., The microRNA-183-96-182 cluster promotes T helper 17 cell pathogenicity by negatively regulating transcription factor Foxo1 expression. Immunity 44 (2016), 1284–1298.
12. Pasare, C., Medzhitov, R., Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299 (2003), 1033–1036.
13. Goodman, W.A., Levine, A.D., Massari, J.V., Sugiyama, H., McCormick, T.S., Cooper, K.D., IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 183 (2009), 3170–3176.
14. Schneider, A., Long, S.A., Cerosaletti, K., Ni, C.T., Samuels, P., Kita, M., Buckner, J.H., In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling. Sci Transl Med, 5, 2013, 170ra.
15. Ferreira, R.C., Rainbow, D.B., Rubio Garcia, A., Pekalski, M.L., Porter, L., Oliveira, J.J., Waldron-Lynch, F., Wicker, L.S., Todd, J.A., Human IL-6R(hi)TIGIT(-) CD4(+)CD127(low)CD25(+) T cells display potent in vitro suppressive capacity and a distinct Th17 profile. Clin Immunol 179 (2017), 25–39.
16. Heink, S., Yogev, N., Garbers, C., Herwerth, M., Aly, L., Gasperi, C., Husterer, V., Croxford, A.L., Moller-Hackbarth, K., Bartsch, H.S., et al. Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. Nat Immunol 18 (2017), 74–85 Initial characterization of cluster signaling in dendritic cells.
17. Li, D., Kong, C., Tsun, A., Chen, C., Song, H., Shi, G., Pan, W., Dai, D., Shen, N., Li, B., MiR-125a-5p decreases the sensitivity of Treg cells toward IL-6-mediated conversion by inhibiting IL-6R and STAT3 expression. Sci Rep, 5, 2015, 14615.
18. Venigalla, R.K., Tretter, T., Krienke, S., Max, R., Eckstein, V., Blank, N., Fiehn, C., Ho, A.D., Lorenz, H.M., Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127-/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum 58 (2008), 2120–2130.
19. Schneider, A., Rieck, M., Sanda, S., Pihoker, C., Greenbaum, C., Buckner, J.H., The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol 181 (2008), 7350–7355.
20. Ihantola, E.-L., Viisanen, T., Gazali, A.M., Näntö-Salonen, K., Juutilainen, A., Moilanen, L., Rintamäki, R., Pihlajamäki, J., Veijola, R., Toppari, J., Effector T cell resistance to suppression and STAT3 signaling during the development of human type 1 diabetes. J Immunol, 2018 ji1701199 Teff resistance in T1D patients is STAT3-dependent but not linked to the capacity of Teffs to produce or respond to IL-6.
21. Haufe, S., Schepp, C., Kuemmerle-Deschner, J., Hansmann, S., Rieber, N., Tzaribachev, N., Hospach, T., Maier, J., Dannecker, G.E., Holzer, U., Impaired suppression of synovial fluid CD4(+) CD25(-) T cells from patients with juvenile idiopathic arthritis by CD4(+) CD25(+) regulatory T cells. Arthritis Rheum 63 (2011), 3153–3162.
22. Tu, E., Chia, C.P., Chen, W., Zhang, D., Park, S.A., Jin, W., Wang, D., Alegre, M.-L., Zhang, Y.E., Sun, L., T cell receptor-regulated TGF-β type I receptor expression determines T cell quiescence and activation. Immunity 48 (2018), 745–759.e746 Novel mechanism involving IL-6 in the enforcement of quiescence in naïve T cells.
23. Rosser, E.C., Oleinika, K., Tonon, S., Doyle, R., Bosma, A., Carter, N.A., Harris, K.A., Jones, S.A., Klein, N., Mauri, C., Regulatory B cells are induced by gut microbiota–driven interleukin-1β and interleukin-6 production. Nat Med, 20, 2014, 1334.
24. Ma, J., Zhu, C., Ma, B., Tian, J., Baidoo, S.E., Mao, C., Wu, W., Chen, J., Tong, J., Yang, M., et al. Increased frequency of circulating follicular helper T cells in patients with rheumatoid arthritis. Clin Dev Immunol, 2012, 2012, 827480.
25. Barr, T.A., Shen, P., Brown, S., Lampropoulou, V., Roch, T., Lawrie, S., Fan, B., O'Connor, R.A., Anderton, S.M., Bar-Or, A., et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 209 (2012), 1001–1010.
26. Arkatkar, T., Du, S.W., Jacobs, H.M., Dam, E.M., Hou, B., Buckner, J.H., Rawlings, D.J., Jackson, S.W., B cell-derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity. J Exp Med 214 (2017), 3207–3217 IL-6 produced by B cells drives formation of germinal centers and Tfh differentiation.
27. de Valle, E., Grigoriadis, G., O'Reilly, L.A., Willis, S.N., Maxwell, M.J., Corcoran, L.M., Tsantikos, E., Cornish, J.K., Fairfax, K.A., Vasanthakumar, A., NFκB1 is essential to prevent the development of multiorgan autoimmunity by limiting IL-6 production in follicular B cells. J Exp Med 213 (2016), 621–641.
28. Narazaki, M., Yasukawa, K., Saito, T., Ohsugi, Y., Fukui, H., Koishihara, Y., Yancopoulos, G.D., Taga, T., Kishimoto, T., Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82 (1993), 1120–1126.
29. Jostock, T., Mullberg, J., Ozbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M., Neurath, M.F., Rose-John, S., Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 268 (2001), 160–167.
30. Lust, J.A., Donovan, K.A., Kline, M.P., Greipp, P.R., Kyle, R.A., Maihle, N.J., Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 4 (1992), 96–100.
31. Briso, E.M., Dienz, O., Rincon, M., Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J Immunol 180 (2008), 7102–7106.
32. Veldhoen, M., Hocking, R.J., Atkins, C.J., Locksley, R.M., Stockinger, B., TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24 (2006), 179–189.
33. Rabe, B., Chalaris, A., May, U., Waetzig, G.H., Seegert, D., Williams, A.S., Jones, S.A., Rose-John, S., Scheller, J., Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 111 (2008), 1021–1028.
34. Samson, M., Audia, S., Janikashvili, N., Ciudad, M., Trad, M., Fraszczak, J., Ornetti, P., Maillefert, J.F., Miossec, P., Bonnotte, B., Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 64 (2012), 2499–2503.
35. Quintana, F.J., Old dog, new tricks: IL-6 cluster signaling promotes pathogenic TH17 cell differentiation. Nat Immunol 18 (2016), 8–10.
36. van Dongen, J., Jansen, R., Smit, D., Hottenga, J.J., Mbarek, H., Willemsen, G., Kluft, C., Collaborators, A., Penninx, B.W., Ferreira, M.A., et al. The contribution of the functional IL6R polymorphism rs2228145, eQTLs and other genome-wide SNPs to the heritability of plasma sIL-6R levels. Behav Genet 44 (2014), 368–382.
37. Amaral, W.Z., Krueger, R.F., Ryff, C.D., Coe, C.L., Genetic and environmental determinants of population variation in interleukin-6, its soluble receptor and C-reactive protein: insights from identical and fraternal twins. Brain Behav Immun 49 (2015), 171–181.
38. Garbers, C., Monhasery, N., Aparicio-Siegmund, S., Lokau, J., Baran, P., Nowell, M.A., Jones, S.A., Rose-John, S., Scheller, J., The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. Biochim Biophys Acta 1842 (2014), 1485–1494.
39. Ferreira, R.C., Freitag, D.F., Cutler, A.J., Howson, J.M., Rainbow, D.B., Smyth, D.J., Kaptoge, S., Clarke, P., Boreham, C., Coulson, R.M., et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLoS Genet, 9, 2013, e1003444.
40. Hundhausen, C., Roth, A., Whalen, E., Chen, J., Schneider, A., Long, S.A., Wei, S., Rawlings, R., Kinsman, M., Evanko, S.P., et al. Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression. Sci Transl Med, 8, 2016, 356ra A role for dysregulated IL-6 responsiveness in the pathogenesis of type 1 diabetes.
41. Nishimoto, N., Yoshizaki, K., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Hashimoto, J., Azuma, J., Kishimoto, T., Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: a multicenter, double‐blind, placebo‐controlled trial. Arthritis Rheum 50 (2004), 1761–1769.
42. Calabrese, L.H., Rose-John, S., IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 10 (2014), 720–727.
43. Khanna, D., Denton, C.P., Jahreis, A., van Laar, J.M., Frech, T.M., Anderson, M.E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387 (2016), 2630–2640.
44. Araki, M., Matsuoka, T., Miyamoto, K., Kusunoki, S., Okamoto, T., Murata, M., Miyake, S., Aranami, T., Yamamura, T., Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 82 (2014), 1302–1306.
45. Genovese, M.C., Fleischmann, R., Kivitz, A.J., Rell-Bakalarska, M., Martincova, R., Fiore, S., Rohane, P., van Hoogstraten, H., Garg, A., Fan, C., Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheum 67 (2015), 1424–1437.
46. van Rhee, F., Wong, R.S., Munshi, N., Rossi, J.F., Ke, X.Y., Fossa, A., Simpson, D., Capra, M., Liu, T., Hsieh, R.K., et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 15 (2014), 966–974.
47. Torices, S., Julia, A., Munoz, P., Varela, I., Balsa, A., Marsal, S., Fernandez-Nebro, A., Blanco, F., Lopez-Hoyos, M., Martinez-Taboada, V., et al. A functional variant of TLR10 modifies the activity of NFkB and may help predict a worse prognosis in patients with rheumatoid arthritis. Arthritis Res Ther, 18, 2016, 221.
48. Mease, P.J., Gottlieb, A.B., Berman, A., Drescher, E., Xing, J., Wong, R., Banerjee, S., The efficacy and safety of Clazakizumab, an anti–interleukin‐6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis. Arthritis Rheum 68 (2016), 2163–2173.
49. Orlowski, R.Z., Gercheva, L., Williams, C., Sutherland, H., Robak, T., Masszi, T., Goranova-Marinova, V., Dimopoulos, M.A., Cavenagh, J.D., Spicka, I., et al. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol 90 (2015), 42–49.
50. Shah, J.J., Feng, L., Thomas, S.K., Berkova, Z., Weber, D.M., Wang, M., Qazilbash, M.H., Champlin, R.E., Mendoza, T.R., Cleeland, C., et al. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J, 6, 2016, e396.
51. Kennedy Crispin, M., Ko, J.M., Craiglow, B.G., Li, S., Shankar, G., Urban, J.R., Chen, J.C., Cerise, J.E., Jabbari, A., Winge, M.C., et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight, 1, 2016, e89776.
52. Bachelez, H., van de Kerkhof, P.C., Strohal, R., Kubanov, A., Valenzuela, F., Lee, J.H., Yakusevich, V., Chimenti, S., Papacharalambous, J., Proulx, J., et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 386 (2015), 552–561.
53. Kivitz, A., Gutierrez-Ureña, S., Poiley, J., Genovese, M., Kristy, R., Shay, K., Wang, X., Garg, J., Zubrzycka-Sienkiewicz, A., Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheum 69 (2017), 709–719.
54. Kikuchi, J., Hashizume, M., Kaneko, Y., Yoshimoto, K., Nishina, N., Takeuchi, T., Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response. Arthritis Res Ther, 17, 2015, 10.
55. Tada, Y., Ono, N., Suematsu, R., Tashiro, S., Sadanaga, Y., Tokuda, Y., Ono, Y., Nakao, Y., Maruyama, A., Ohta, A., et al. The balance between Foxp3 and Ror-gammat expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis. BMC Musculoskelet Disord, 17, 2016, 290 The ratio of Foxp3/Ror-ɣt decreased after abatacept treatment and increased after treatment with tocilizumab.
56. Thiolat, A., Semerano, L., Pers, Y., Biton, J., Lemeiter, D., Portales, P., Quentin, J., Jorgensen, C., Decker, P., Boissier, M.C., Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheum 66 (2014), 273–283.
57. Daïen, C.I., Gailhac, S., Audo, R., Mura, T., Hahne, M., Combe, B., Morel, J., High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis. Rheumatology 54 (2014), 601–608.
58. Weinhold, K.J., Bukowski, J.F., Brennan, T.V., Noveck, R.J., Staats, J.S., Lin, L., Stempora, L., Hammond, C., Wouters, A., Mojcik, C.F., et al. Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers. Clin Immunol 191 (2018), 10–20.
59. Rizzi, M., Lorenzetti, R., Fischer, K., Staniek, J., Janowska, I., Troilo, A., Strohmeier, V., Erlacher, M., Kunze, M., Bannert, B., et al. Impact of tofacitinib treatment on human B-cells in vitro and in vivo. J Autoimmun 77 (2017), 55–66.
60. Lyman, M., Lieuw, V., Richardson, R., Timmer, A., Stewart, C., Granger, S., Woods, R., Silacci, M., Grabulovski, D., Newman, R., A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases. J Biol Chem 293 (2018), 9326–9334 Novel therapeutic targeting of IL-17A and IL-6R with potential for enhanced efficiency.